Annual report [Section 13 and 15(d), not S-K Item 405]

Consolidated Statements of Stockholders' Equity

v3.26.1
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
Noncontrolling Interest [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2023 $ 6 $ 19,406 $ 469 $ (14,715) $ 5,166
Balance, shares at Dec. 31, 2023 5,741,838        
Stock-based compensation 280 280
Stock-based compensation, shares 90,860        
Restricted stock issuances 87 87
Restricted stock issuances, shares 53,410        
Shares issued in acquisition 200 200
Shares issued in acquisition, shares 89,892        
Exercise of warrants
Exercise of warrants, shares 5,439        
Issuance of securities $ 2 3,770 3,772
Issuance of securities, shares 1,657,058        
Non-controlling interest contribution 38 38
Net loss (182) (3,281) (3,463)
Balance at Dec. 31, 2024 $ 8 23,743 325 (17,996) 6,080
Balance, shares at Dec. 31, 2024 7,638,497        
Stock-based compensation 475 $ 475
Stock-based compensation, shares 6,825       907,111
Restricted stock issuances 179 $ 179
Restricted stock issuances, shares 39,116       60,456
Issuance of securities 963 $ 963
Issuance of securities, shares 458,695        
Net loss 107 (3,000) (2,893)
Warrants issued in conjunction with NexgelRx 87 87
Balance at Dec. 31, 2025 $ 8 $ 25,447 $ 432 $ (20,996) $ 4,891
Balance, shares at Dec. 31, 2025 8,143,133